Literature DB >> 3032503

In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir.

N L Cole, H H Balfour.   

Abstract

Fifty-four isolates of cytomegalovirus (CMV) from 25 immunocompromised patients with CMV infections were examined in a plaque reduction assay to determine in vitro susceptibilities to both acyclovir and ganciclovir. Isolates were approximately 25-fold more sensitive to ganciclovir than to acyclovir. The mean +/- SD ID50 for all isolates to acyclovir was 63.1 +/- 30.2 microM, (median, 52.3 microM; range, 16.7-146.4 microM). The mean ID50 for all isolates to ganciclovir was 2.50 +/- 1.27 microM, (median, 2.15 microM; range, 0.65-7.11 microM). Exposure to acyclovir or ganciclovir for periods of 2-5 wk did not alter the mean susceptibility of clinical isolates. However, one CMV strain isolated from a renal transplant patient after 14 days of acyclovir therapy displayed the lowest susceptibility of all strains tested (acyclovir 146.4 microM; ganciclovir 7.11 microM) and may represent selection of a resistant virus population.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032503     DOI: 10.1016/0732-8893(87)90020-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  18 in total

1.  Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures.

Authors:  J M Pepin; F Simon; A Dussault; G Collin; M C Dazza; F Brun-Vezinet
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

2.  Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor.

Authors:  Takehiko Mori; Yoshinobu Aisa; Takayuki Shimizu; Tomonori Nakazato; Rie Yamazaki; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 3.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

4.  Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.

Authors:  C L Talarico; T C Burnette; W H Miller; S L Smith; M G Davis; S C Stanat; T I Ng; Z He; D M Coen; B Roizman; K K Biron
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 5.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 6.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

7.  Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.

Authors:  Heather E Vezina; Richard C Brundage; Henry H Balfour
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

8.  Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.

Authors:  M A Slavin; R R Bindra; C A Gleaves; M B Pettinger; R A Bowden
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 9.  Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.

Authors:  Nancy Perrottet; Laurent A Decosterd; Pascal Meylan; Manuel Pascual; Jerome Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Toxicity trial of prophylactic 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine (ganciclovir) after marrow transplantation in dogs.

Authors:  F R Appelbaum; J D Meyers; H J Deeg; T Graham; F Schuening; R Storb
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.